Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder
NCT06229210Phase 3Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Jan 2024
- Primary completion
- Apr 2032
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of lumateperone in schizophrenia, bipolar disorder (BD), Autism Spectrum Disorder (ASD), sponsored by Intra-Cellular Therapies. Started Jan 2024; status: recruiting.
02
Drugs
lumateperone
03
Conditions
schizophreniabipolar disorder (BD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06229210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229210.